Following NCPE assessment of the Applicant’s submission, cost effectiveness of pertuzumab (Perjeta®) (in combination with trastuzumab and chemotherapy) for this indication has not been demonstrated. Therefore it is not recommended for reimbursement.
The NCPE does not recommend reimbursement of Apremilast (Otezla®) for psoriatic arthritis at the submitted price.
The NCPE does not recommend reimbursement of Ataluren (Translarna®).
Reimbursement not Recommended at the Submitted Price.
The NCPE does not recommend reimbursement Nivolumab (Opdivio®) at the submitted price.
The NCPE does not recommend reimbursement of nivolumab (Opdivo®) at the submitted price.
The NCPE does not recommend reimbursement of Nintedanib (Ofev®) at the submitted price.
The NCPE do not recommend reimbursement of Idelalisib (Zydelig®)
The NCPE recommends reimbursement in certain sub-populations of patients with genotype 1 & 4.
The NCPE recommends reimbursement of pembrolizumb for the first line treatment of unresectable or advanced metastic melanoma.